Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response - Wikidata - awgldk - TriplyDB

Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response

Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response

http://www.wikidata.org/entity/Q35109141

about

Imaging of HCC-Current State of the Art Combining radiotherapy with sunitinib: lessons (to be) learned Prognostication and response assessment in liver and pancreatic tumors: The new imaging Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma Multiparametric MR Imaging in Abdominal Malignancies.Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study.Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes.Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker.Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.Data-driven mapping of hypoxia-related tumor heterogeneity using DCE-MRI and OE-MRI.Roles of RUNX in Hypoxia-Induced Responses and Angiogenesis.Contrast agents in dynamic contrast-enhanced magnetic resonance imaging.Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy.Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma.Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: a preliminary study of the correlations between quantitative parameters and clinical stage.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.DCE-MRI-Derived Volume Transfer Constant (Ktrans) and DWI Apparent Diffusion Coefficient as Predictive Markers of Short- and Long-Term Efficacy of Chemoradiotherapy in Patients With Esophageal Cancer.

P2860

Q26768463-C65914D3-F0B0-45F9-AAD8-1DB4AF0AB436 Q26800587-F1BCB483-17B1-49B9-BA98-206E93E5FA56 Q27021568-F10B7020-3031-427E-89EF-B0F27EE34EF9 Q27025007-7A205BA8-7F30-4A1C-B404-60308EED6F96 Q28068654-78D489DF-12B4-4D5C-863D-7563697AF2F9 Q28301777-4AE1C2D2-2DD2-4DD4-A31E-B1E467DDE788 Q30364605-DFA7BB3B-0075-4E61-AD8F-CD9F04F751E1 Q30448049-2288DE1A-F56A-42E3-A941-C006528DEE30 Q30575110-8A7F253F-A8D2-47E3-8F8D-4967BB7FDB07 Q31030824-E24F5BC5-5080-4FA1-9A4D-2874B5B46F16 Q31119452-E5D9401F-D72D-4E7B-AA04-7F66E3FE8817 Q33688593-D393A2B8-B41C-41E7-AB35-4498704C1DCE Q34089545-8964A831-0110-484A-8CD5-74D770EE081B Q34331739-ADEE57BE-5D91-417E-BF6A-2D7339B0F4A7 Q34465123-E0E53BA9-0DB7-45D0-880C-509CAC0BEE51 Q35710375-12C2434E-1BC3-4091-B51B-4E27E877D59A Q35772492-2B6C290B-03F9-44EA-9525-E2E621660E09 Q35892542-F7CF850A-B79D-4153-90ED-35B0E1F13400 Q35929346-0119A34A-01E4-4661-97CA-64E947FDBAE2 Q36419100-FFACB6EE-C91A-48D1-9681-0D754F556148 Q36641544-66A35A4B-8C30-431B-8CBC-7D968EE52281 Q37141152-7D2B473B-0367-4D2E-8B93-5E7ECD949902 Q37153834-7FCE76C7-9427-47CB-BFD0-F642F799E9A4 Q37660658-79677DA5-7674-4DE1-AED2-757AE855F719 Q38036127-7FDDB50C-5A45-4C66-B8FB-877454C7520B Q38600887-75285D52-A41D-4F14-A53F-FA75C4F95D85 Q39181432-0DBB20A1-30ED-49EB-A648-2C816488C709 Q39246340-4B53A30D-BDA2-435B-B30E-75A86C518A34 Q44004251-A62C25CC-A007-4AE2-89F3-858C8B67D079 Q47114557-84112E08-29A8-42D2-A4BF-C444D8CF6BF6 Q47192935-0648B5D0-7D98-4EFB-9B8B-ADB72C33AAB2 Q51155388-965FB0CB-2EF9-48BA-8562-186A269BD7BE Q52149377-9913E787-4072-42CE-A4AA-1FC4FC697E21 Q53696357-A1552426-E515-46DD-8A70-7A232FB1C236

P2860

Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response

http://www.wikidata.org/entity/Q35109141

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Antiangiogenic therapy for pri ...... markers and clinical response

@ast

Antiangiogenic therapy for pri ...... markers and clinical response

@en

type

label

Antiangiogenic therapy for pri ...... markers and clinical response

@ast

Antiangiogenic therapy for pri ...... markers and clinical response

@en

prefLabel

Antiangiogenic therapy for pri ...... markers and clinical response

@ast

Antiangiogenic therapy for pri ...... markers and clinical response

@en

P1433

Q35109141-DA280010-8C53-446B-90D2-EC18EE4930F0

P1476

Q35109141-7131A793-4752-4F45-AFEB-2EB583E51FCF

P2093

Q35109141-08538842-66CD-4EC2-BB69-E39C21B9F8F5

Q35109141-1E2D1D49-4F88-4539-A48E-54B847C61D9B

Q35109141-23937E01-27B3-47E0-9B92-24F307001290

Q35109141-2EE294B5-C56C-48E8-B744-FE44B056EBAA

Q35109141-33052099-3996-4FA8-BBE1-0629F7676969

Q35109141-52C1359D-1F01-4815-844A-3B5D88A09163

Q35109141-7AF19A82-075B-4207-A3D6-AEE5D28E7ECD

Q35109141-7C75300C-B0FC-47B2-9DEB-AA01398B977C

Q35109141-89FD420B-1A3B-4CF2-919A-F8C214F8A316

Q35109141-A20BBB66-0AE5-4D06-A9A3-4240A0230DFD

P2860

Q35109141-0018E7D6-6AFC-47C1-B2D5-DB21D967437A

Q35109141-03869005-1761-47E2-AED4-4C14F1ABC40D

Q35109141-09C75CBA-4DEA-4DBB-B513-73915AD82C49

Q35109141-19776683-9E7D-4821-9FFC-085F92A6950D

Q35109141-22938568-A5F8-4F6F-BCFE-D9F1D5F43686

Q35109141-31D3EF57-45FB-4872-BB1B-7FBAC23F9ECF

Q35109141-4161CC0F-AF5C-4EFE-AFF5-0EEC789E40B6

Q35109141-4E7E7602-9FFB-4DDF-8EFE-174BE9EC1C49

Q35109141-5259093A-AD48-4C21-BA1A-5529746C4AF9

Q35109141-53601363-4D58-4CCE-ABB2-A9136488AB80

P2888

Q35109141-79F24527-80DB-4803-BF45-A4466A368B17

P304

Q35109141-90FA044B-6827-40CB-A801-0C82B35848D7

P31

Q35109141-CBBA26F6-BCE1-4181-A1F2-B781C6017FF0

P356

Q35109141-D20A9987-B96C-473C-A365-0BA304FA0813

P433

Q35109141-6AB5AF5B-4CC6-4E4D-AA15-B3590C7676A9

P478

Q35109141-6A13DA86-3ECC-497C-8A19-6A2429FBADAB

P50

Q35109141-6D6A24ED-F764-4A8C-9A18-194A0E631BB8

Q35109141-BDF340E2-D9FB-40A9-8016-42872612CC0F

P577

Q35109141-8D374795-C94A-41C8-B7E5-72B7DD7B9509

P5875

Q35109141-04C81B04-258E-48B6-B92B-CEFBA5310871

P6179

Q35109141-6ECFFA59-5A27-4D64-A5F2-1FA71668EAE7

P698

Q35109141-D3E7659D-7E22-4FAD-8207-80FF6CF3A2BF

P932

Q35109141-5D022987-3921-4484-B007-4437790ACCF7

P356

S10434-011-1570-1

P1433

Annals of Surgical Oncology

P1476

Antiangiogenic therapy for pri ...... markers and clinical response

@en

P2093

Adam C Yopp

http://www.w3.org/2001/XMLSchema#string

Dana Haviland

http://www.w3.org/2001/XMLSchema#string

David H Gultekin

http://www.w3.org/2001/XMLSchema#string

Jinru Shia

http://www.w3.org/2001/XMLSchema#string

Lawrence H Schwartz

http://www.w3.org/2001/XMLSchema#string

Michael I D'Angelica

http://www.w3.org/2001/XMLSchema#string

Mithat Gönen

http://www.w3.org/2001/XMLSchema#string

Nancy Kemeny

http://www.w3.org/2001/XMLSchema#string

Peter J Allen

http://www.w3.org/2001/XMLSchema#string

Ronald P DeMatteo

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of noninvasive imaging surrogates for brain tumor gene-expression modules

Targeting HIF-1 for cancer therapy

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

P2888

s10434-011-1570-1

P304

2192-2199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-011-1570-1

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49803655

http://www.w3.org/2001/XMLSchema#string

P6179

1012237972

http://www.w3.org/2001/XMLSchema#string

P698

21286939

http://www.w3.org/2001/XMLSchema#string

P932

3137666

http://www.w3.org/2001/XMLSchema#string